Fexinidazole Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the excretion of fexinidazole into breastmilk. The manufacturer reports that no adverse effects to the breastfed child have been associated with fexinidazole exposure through breastmilk based on a limited number of reported cases. If a mother requires fexinidazole, it is not a reason to discontinue breastfeeding. Until more data are available, fexinidazole should only be used with careful infant monitoring during breastfeeding, including for vomiting, insomnia, nausea, tremor, and decreased appetite.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
According to the manufacturer, no adverse effects to the breastfed child have been associated with fexinidazole exposure through breastmilk based on a limited number of reported cases.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Fexinidazole
CAS Registry Number
59729-37-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Infective Agents
Antiprotozoal Agents
Nitroimidazoles
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
